Cingulate Inc (CING)

Jun 18, 2025

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING) - TradingView

Jun 18, 2025

Jun 18, 2025

Breakthrough Once-Daily ADHD Drug Targets $22B Market: Analyst Coverage Reveals Commercial Launch Plans - Stock Titan

Jun 18, 2025

Jun 14, 2025

Cingulate Inc. (NASDAQ:CING) Sees Large Increase in Short Interest - Defense World

Jun 14, 2025

Jun 13, 2025

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets - mx.advfn.com

Jun 13, 2025

Jun 13, 2025

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 - mx.advfn.com

Jun 13, 2025

Jun 11, 2025

Cingulate Inc. expands equity plan following stockholder approval - Investing.com

Jun 11, 2025

Jun 11, 2025

Cingulate Inc Approves Key Proposals at Annual Meeting - TipRanks

Jun 11, 2025

May 28, 2025

Cingulate (NASDAQ:CING) Price Target Raised to $61.00 at Ascendiant Capital Markets - Defense World

May 28, 2025

May 27, 2025

Life365 Appoints Healthcare Veteran Jay Roberts as Chief Development Officer - Quantisnow

May 27, 2025

May 27, 2025

CING: Ascendiant Capital Raises Price Target to $61.00 | CING St - GuruFocus

May 27, 2025

May 27, 2025

Healthcare Tech Leader Life365 Taps Former Nasdaq CEO Jay Roberts to Drive AI-Powered Growth Strategy - Stock Titan

May 27, 2025

May 22, 2025

What is Roth Capital’s Estimate for Cingulate Q2 Earnings? - Defense World

May 22, 2025

May 21, 2025

McCann Joburg acquires a healthcare marketing company - Bizcommunity

May 21, 2025

May 20, 2025

Cingulate Reports Positive Data From Phase 3 Study Of CTx-1301 In Pediatric ADHD - Nasdaq

May 20, 2025

May 20, 2025

Cingulate announces efficacy results from Phase 3 study of CTx-1301 - TipRanks

May 20, 2025

May 20, 2025

Cingulate (CING) Reveals Promising Phase 3 Results for ADHD Treatment | CING Stock News - GuruFocus

May 20, 2025

May 20, 2025

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD - GlobeNewswire

May 20, 2025

May 19, 2025

CING: Roth Capital Lowers Price Target, Maintains Buy Rating | CING Stock News - GuruFocus

May 19, 2025

May 18, 2025

CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developm - GuruFocus

May 18, 2025

May 18, 2025

Cingulate price target lowered to $11 from $12 at Roth Capital - TipRanks

May 18, 2025

May 18, 2025

CING: Roth Capital Adjusts Price Target Amidst CTx-1301 Developments | CING Stock News - GuruFocus

May 18, 2025

May 16, 2025

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug - MSN

May 16, 2025

May 15, 2025

CING: First Quarter 2025 Results - Yahoo Finance

May 15, 2025

May 15, 2025

Cingulate receives FDA meeting feedback on ADHD drug By Investing.com - Investing.com Canada

May 15, 2025

May 15, 2025

Cingulate Retail Buzz Rises After FDA Greenlights Summer NDA Filing For ADHD Drug By Stocktwits - Investing.com India

May 15, 2025

May 15, 2025

Cingulate, Inc. Reports Increased Losses Amid R&D Expansion - TipRanks

May 15, 2025

May 14, 2025

Cingulate receives formal pre-NDA meeting minutes from FDA for CTx-1301 - TipRanks

May 14, 2025

May 14, 2025

Cingulate (CING) Prepares for NDA Submission for ADHD Treatment - GuruFocus

May 14, 2025

May 14, 2025

Cingulate receives FDA meeting feedback on ADHD drug - Investing.com

May 14, 2025

May 14, 2025

Cingulate Inc Terminates Grant Agreement with Foundation - TipRanks

May 14, 2025

May 08, 2025

Cingulate Inc. Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025

May 05, 2025

27,323 Shares in Cingulate Inc. (NASDAQ:CING) Acquired by Geode Capital Management LLC - Defense World

May 05, 2025

Apr 30, 2025

Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301 - TipRanks

Apr 30, 2025

Apr 30, 2025

CING Reports Positive Results for CTx-1301 in Food Effect Study - GuruFocus

Apr 30, 2025

Apr 29, 2025

Cingulate announces results from high-dose fed/fast study of CTx-1301 - TipRanks

Apr 29, 2025

Apr 29, 2025

Cingulate Announces Positive Top-Line Results from - GlobeNewswire

Apr 29, 2025

Apr 29, 2025

Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd - marketscreener.com

Apr 29, 2025

Apr 29, 2025

Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - The Manila Times

Apr 29, 2025

Apr 22, 2025

Cingulate (NASDAQ:CING) Given New $60.00 Price Target at Ascendiant Capital Markets - Defense World

Apr 22, 2025

Apr 11, 2025

Analysts’ Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING) - The Globe and Mail

Apr 11, 2025

Apr 10, 2025

Cingulate secures $3m to advance once-daily anxiety treatment - Yahoo Finance

Apr 10, 2025

Apr 10, 2025

Cingulate wins $3M from private foundation to help develop third time-release drug - The Business Journals

Apr 10, 2025

Apr 10, 2025

CING: 2024 Financial and Operational Results - Yahoo Finance

Apr 10, 2025

Apr 10, 2025

Cingulate Inc. (NASDAQ:CING) Shares Purchased by Commonwealth Equity Services LLC - Defense World

Apr 10, 2025

Apr 09, 2025

Cingulate Inc Secures $3M Grant for Anxiety Drug - TipRanks

Apr 09, 2025

Apr 09, 2025

Cingulate Receives $3 Million Grant from Private Foundation - GlobeNewswire

Apr 09, 2025

Apr 09, 2025

Revolutionary Once-Daily Anxiety Drug Gets $3M Boost: Targeting $5.5B Market - Stock Titan

Apr 09, 2025